- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Fulcrum Therapeutics Inc (FULC)
Fulcrum Therapeutics Inc stock price live, this page displays NASDAQ FULC stock exchange data. View the FULC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Fulcrum Therapeutics Inc real time stock price chart below.
What Is the Fulcrum Therapeutics Inc Stock Price Today?
The Fulcrum Therapeutics Inc stock price today is 6.480.
What Is the Stock Symbol for Fulcrum Therapeutics Inc?
The stock symbol for Fulcrum Therapeutics Inc is ""FULC.""
What Stock Exchange Does Fulcrum Therapeutics Inc Trade On?
Fulcrum Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Fulcrum Therapeutics Inc a Good Stock to Buy?
Determining whether Fulcrum Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FULC quote. (ISIN: US3596161097)
What Is the Fulcrum Therapeutics Inc Stock Price Today?
The Fulcrum Therapeutics Inc stock price today is 6.480.
What Is the Stock Symbol for Fulcrum Therapeutics Inc?
The stock symbol for Fulcrum Therapeutics Inc is ""FULC.""
What Stock Exchange Does Fulcrum Therapeutics Inc Trade On?
Fulcrum Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Fulcrum Therapeutics Inc a Good Stock to Buy?
Determining whether Fulcrum Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FULC quote. (ISIN: US3596161097)
Fair Value
An estimate of a Fulcrum Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.400
6.710
52 wk Range
2.315
9.300
FULC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
FULC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Fulcrum Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.4006.710
52 wk Range
2.3159.300
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
FULC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Fulcrum Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
11.071
Upside
+70.86%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Fulcrum Therapeutics Inc Company Profile
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fulcrum Therapeutics Inc SWOT Analysis
Pipeline Pivot | Explore Fulcrum's strategic shift following losmapimod's Phase III trial setback, focusing on pociredir for Sickle Cell Disease and early-stage programs |
Financial Resilience | Despite recent challenges, Fulcrum maintains strong liquidity with more cash than debt and a healthy current ratio of 18.44 |
Market Volatility | Fulcrum's stock experiences significant fluctuations, with analyst price targets ranging from $2 to $14, reflecting diverse views on future prospects |
Growth Potential | Delve into Fulcrum's proprietary pipeline and expertise in rare genetic disorders, which could lead to valuable partnerships and licensing agreements |
Fulcrum Therapeutics Inc Earnings Call Summary for Q1/2025
- Net loss improved to $17.7M from $26.9M in Q1 2024, with R&D expenses down $6.4M
- Stock fell 5.71% premarket after slight EPS miss of -$0.28 vs -$0.26 forecast
- Cash runway extended into 2027; strong financial health score of 3.26 rated 'GREAT'
- Lead sickle cell program progressing; 12mg cohort data expected early Q3 2025
- CEO emphasized fetal hemoglobin induction as optimal strategy for sickle cell treatment
Last Updated: 01/05/2025, 13:50
Read Full TranscriptCompare FULC to Peers and Sector
Metrics to compare | FULC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFULCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.8x | 3.5x | −0.5x | |
PEG Ratio | 0.02 | 0.18 | 0.00 | |
Price/Book | 1.6x | 1.2x | 2.6x | |
Price / LTM Sales | - | 2.5x | 3.3x | |
Upside (Analyst Target) | 85.2% | 32.8% | 38.9% | |
Fair Value Upside | Unlock | 22.4% | 5.4% | Unlock |
Analyst Ratings
5 Buy
1 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 11.071
(+70.86% Upside)
Earnings
Latest Release
Jul 29, 2025
EPS / Forecast
-0.28 / -0.29
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Fulcrum Therapeutics Trade On?
Fulcrum Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Fulcrum Therapeutics?
The stock symbol for Fulcrum Therapeutics is "FULC."
What Is the Fulcrum Therapeutics Market Cap?
As of today, Fulcrum Therapeutics market cap is 350.51M.
What Is Fulcrum Therapeutics's Earnings Per Share (TTM)?
The Fulcrum Therapeutics EPS (TTM) is -1.18.
When Is the Next Fulcrum Therapeutics Earnings Date?
Fulcrum Therapeutics will release its next earnings report on 11 Nov 2025.
From a Technical Analysis Perspective, Is FULC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Fulcrum Therapeutics Stock Split?
Fulcrum Therapeutics has split 0 times.
How Many Employees Does Fulcrum Therapeutics Have?
Fulcrum Therapeutics has 45 employees.
What is the current trading status of Fulcrum Therapeutics (FULC)?
As of 30 Aug 2025, Fulcrum Therapeutics (FULC) is trading at a price of 6.480, with a previous close of 6.65. The stock has fluctuated within a day range of 6.400 to 6.710, while its 52-week range spans from 2.315 to 9.300.
What Is Fulcrum Therapeutics (FULC) Price Target According to Analysts?
The average 12-month price target for Fulcrum Therapeutics is USD11.07143, with a high estimate of USD15 and a low estimate of USD5. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +70.86% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.